The cell lines were edited with CRISPR/Cas9 to create fusions of GFP with the proteins of interest, allowing researchers to image structures in real time.
The researchers said their one-step, inducible, multiplex gene knockdown and gene knockout platforms can be used in many differentiated cell types.
Evotec will use Merck's collection of genetic reagents — including viral CRISPR and shRNA libraries — in target discovery programs.
Knudra, a model organism engineering firm, will use CRISPR to edit C. elegans and zebrafish genomes for its pharma and biotech customers.
The combined company will be focused on Miragen's microRNA therapeutics programs, following the divestiture of Signal's molecular diagnostic assets.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.